ArticleMolecular therapy. Methods & clinical development2020
A Quantitative
Article in Molecular therapy. Methods & clinical development, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- A Droplet Digital PCR Assay for Quantification of Bacteriophage Viral Vector Titer and Purity.Annals of biomedical engineering · 2026Article
- Assessing the biopotency of the rAAV9 vector In Vitro.PloS one · 2026Article
- A versatile cell line for establishing potency of cell type-specific AAV transgenes.Molecular therapy. Methods & clinical development · 2025Article
- Validation of a quantitative cell-based relative potency assay for LUXTURNA.Molecular therapy. Methods & clinical development · 2025Article
- Development of cell lines with increased susceptibility to diverse adeno-associated viral vectors to enableMolecular therapy. Methods & clinical development · 2025Article
- A Quantitative Approach to Potency Testing for Chimeric Antigen Receptor-Encoding Lentiviral Vectors and Autologous CAR-T Cell Products, Using Flow Cytometry.Pharmaceutics · 2025Article
- Quality assessment strategy development and analytical method selection of GMP grade biological drugs for gene and cell therapy.BBA advances · 2025Review
- Crucial aspects for maintaining rAAV stability.Scientific reports · 2024Article
- An In Vitro RNA Editing-Based Reporter Assay for Transcriptional Activity of Therapeutic Gene in Gene Therapy Products.Molecules (Basel, Switzerland) · 2024Article
- Inducible caspase 9-mediated suicide gene therapy using AAV6 vectors in a murine model of breast cancer.Molecular therapy. Methods & clinical development · 2023Article
- Article
- Potency testing of cell and gene therapy products.Frontiers in medicine · 2023Review
- Analytical methods to characterize recombinant adeno-associated virus vectors and the benefit of standardization and reference materials.Current opinion in biotechnology · 2021Review
- Low efficacy of recombinant SV40 in Ugt1a1-/- mice with severe inherited hyperbilirubinemia.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Potency assessment of clinical-grade vector lots is crucial to support adeno-associated virus (AAV) vector release and is required for future marketing authorization. We have developed and validated a cell-based, quantitative potency assay that detects both transgenic expression and activity of an AAV8-h
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.